Lupin receives USFDA's approval for Extended Phenytoin Sodium Capsules

01 Oct 2019 Evaluate

Lupin has received approval for its Extended Phenytoin Sodium Capsules USP, 100 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Dilantin 100 mg, of Parke-Davis, division of Pfizer Inc.

Extended Phenytoin Sodium Capsules USP, 100 mg (RLD: Dilantin) had annual sales of approximately $105 million in the US (IQVIA MAT June 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2055.05 3.00 (0.15%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×